Advertisement

The European Journal of Health Economics

, Volume 12, Issue 3, pp 205–218 | Cite as

Modelling the costs of care of hypertension in patients with metabolic syndrome and its consequences, in Germany, Spain and Italy

  • Eberhard WilleEmail author
  • Jürgen Scholze
  • Eduardo Alegria
  • Claudio Ferri
  • Sue Langham
  • Warren Stevens
  • David Jeffries
  • Kerstin Uhl-Hochgraeber
Original Paper

Abstract

The presence of metabolic syndrome in patients with hypertension significantly increases the risk of cardiovascular disease, type 2 diabetes and mortality. Our aim is to estimate the economic burden to the health service of metabolic syndrome (MetS) in patients with hypertension and its consequences, in three European countries in 2008, and to forecast future economic burden in 2020 using projected demographic estimates and assumptions around the growth of MetS. An age-, sex- and risk group-structured prevalence-based cost of illness model was developed using the United States Adult Treatment Panel III of the National Cholesterol Education Program criteria to define MetS. Data sources included published information and public use databases on disease prevalence, incidence of cardiovascular events, prevalence of type 2 diabetes, treatment patterns and cost of management in Germany, Spain and Italy. The economic burden to the health service of MetS in patients with hypertension has been estimated at 24,427 €, 1,900 € and 4,877 € million in Germany, Spain and Italy, and is forecast to rise by 59, 179 and 157%, respectively, by 2020. The largest components of costs included the management of prevalent type 2 diabetes and incident cardiovascular events. Mean annual costs per hypertensive patient were around three-fold higher in subjects with MetS compared to those without and rose incrementally with the additional number of MetS components present. In conclusion, the presence of MetS in patients with hypertension significantly inflates economic burden, and costs are likely to increase in the future due to an aging population and an increase in the prevalence of components of MetS.

Keywords

Cost of illness Health care costs Prevalence Metabolic syndrome Hypertension 

JEL Classification

I11 I12 

Notes

Acknowledgement

This study was funded by Bayer Schering Pharma AG.

References

  1. 1.
    Kahn, R., Buse, J., Ferrannini, E., Stern, M.: The metabolic syndrome: time for a critical appraisal: joint statement from the American diabetes association and the European association for the study of diabetes. Diabetes Care 28(9), 2289–2304 (2005)PubMedCrossRefGoogle Scholar
  2. 2.
    Ford, E.S.: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28(7), 1769–1778 (2005)PubMedCrossRefGoogle Scholar
  3. 3.
    Galassi, A., Reynolds, K., He, J.: Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 119(10), 812–819 (2006)PubMedCrossRefGoogle Scholar
  4. 4.
    Sattar, N., Gaw, A., Scherbakova, O., Ford, I., O’Reilly, D.S., Haffner, S.M., Isles, C., Macfarlane, P.W., Packard, C.J., Cobbe, S.M., Shepherd, J.: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation 108(4), 414–419 (2003)PubMedCrossRefGoogle Scholar
  5. 5.
    Isomaa, B., Almgren, P., Tuomi, T., Forsen, B., Lahti, K., Nissen, M., Taskinen, M.R., Groop, L.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24(4), 683–689 (2001)PubMedCrossRefGoogle Scholar
  6. 6.
    Rodriguez-Colon, S.M., Mo, J., Duan, Y., Liu, J., Caulfield, J.E., Jin, X., Liao, D.: Metabolic syndrome clusters and the risk of incident stroke: the atherosclerosis risk in communities (ARIC) study. Stroke 40(1), 200–205 (2009)PubMedCrossRefGoogle Scholar
  7. 7.
    Schillaci, G., Pirro, M., Vaudo, G., Gemelli, F., Marchesi, S., Porcellati, C., Mannarino, E.: Prognostic value of the metabolic syndrome in essential hypertension. J. Am. Coll. Cardiol. 43(10), 1817–1822 (2004)PubMedCrossRefGoogle Scholar
  8. 8.
    Andreadis, E.A., Tsourous, G.I., Tzavara, C.K., Georgiopoulos, D.X., Katsanou, P.M., Marakomichelakis, G.E., Diamantopoulos, E.J.: Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population. Am. J. Hypertens. 20(5), 558–564 (2007)PubMedCrossRefGoogle Scholar
  9. 9.
    Pierdomenico, S.D., Lapenna, D., Di Tommaso, R., Di Carlo, S., Caldarella, M.P., Neri, M., Mezzetti, A., Cuccurullo, F.: Prognostic relevance of metabolic syndrome in hypertensive patients at low-to-medium risk. Am. J. Hypertens. 20(12), 1291–1296 (2007)PubMedCrossRefGoogle Scholar
  10. 10.
    Segura, J., Banegas, J.R., Garcia-Donaire, J.A., Rodriguez-Artalejo, F., de la Cruz, J.J., Praga, M., Ruilope, L.M.: Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome? J. Clin. Hypertens. (Greenwich.) 9(8), 595–600 (2007)CrossRefGoogle Scholar
  11. 11.
    Redon, J., Cifkova, R., Laurent, S., Nilsson, P., Narkiewicz, K., Erdine, S., Mancia, G.: The metabolic syndrome in hypertension: European society of hypertension position statement. J. Hypertens. 26(10), 1891–1900 (2008)PubMedCrossRefGoogle Scholar
  12. 12.
    Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A.M., Kjeldsen, S.E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R.E., Struijker Boudier, H.A., Zanchetti, A., Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S.D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J.L., Kjeldsen, S.E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A.M., Laurent, S., Lindholm, L.H., Mancia, G., Manolis, A., Nilsson, P.M., Redon, J., Schmieder, R.E., Struijker-Boudier, H.A., Viigimaa, M., Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.M., Manolis, A.J., Nilsson, P.M., O’Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J.L.: The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 28(12), 1462–1536 (2007)PubMedGoogle Scholar
  13. 13.
    Cordero, A., Laclaustra, M., Leon, M., Grima, A., Casasnovas, J.A., Luengo, E., del Rio, A., Ferreira, I., Alegria, E.: Prehypertension is associated with insulin resistance state and not with an initial renal function impairment. A metabolic syndrome in active subjects in Spain (MESYAS) registry substudy. Am. J. Hypertens. 19(2), 189–196 (2006)PubMedCrossRefGoogle Scholar
  14. 14.
    Ferrara, L.A., Cardoni, O., Mancini, M., Zanchetti, A.: Metabolic syndrome and left ventricular hypertrophy in a general population. Results from the gubbio study. J. Hum. Hypertens. 21(10), 795–801 (2007)PubMedCrossRefGoogle Scholar
  15. 15.
    Mancia, G., Parati, G., Borghi, C., Ghironzi, G., Andriani, E., Marinelli, L., Valentini, M., Tessari, F., Ambrosioni, E.: Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J. Hypertens. 24(5), 837–843 (2006)PubMedCrossRefGoogle Scholar
  16. 16.
    Mancia, G., Bombelli, M., Corrao, G., Facchetti, R., Madotto, F., Giannattasio, C., Trevano, F.Q., Grassi, G., Zanchetti, A., Sega, R.: Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 49(1), 40–47 (2007)PubMedCrossRefGoogle Scholar
  17. 17.
    Barrios, V., Escobar, C., Calderon, A., Llisterri, J.L., Alegria, E., Muniz, J., Matali, A.: Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis. J. Cardiometab. Syndr. 2(1), 9–15 (2007)PubMedCrossRefGoogle Scholar
  18. 18.
    Romero, R., Bonet, J., de la Sierra, A., Aguilera, M.T., Esopoh Study, I.: Undiagnosed obesity in hypertension: clinical and therapeutic implications. Blood Press. 16(6), 347–353 (2007)PubMedCrossRefGoogle Scholar
  19. 19.
    Navarro, J., Redon, J., Cea-Calvo, L., Lozano, J.V., Fernandez-Perez, C., Bonet, A., Gonzalez-Esteban, J.: Metabolic syndrome, organ damage and cardiovascular disease in treated hypertensive patients. The ERIC-HTA study. Blood Press. 16(1), 20–27 (2007)PubMedCrossRefGoogle Scholar
  20. 20.
    de la Sierra, A., Romero, R., Bonet, J., Perez, M., Lopez, J.S., Ravella, R., Aguilera, M.T.: Prevalence and general features of the metabolic syndrome in the Spanish hypertensive population. Med. Clin. (Barc.) 126(11), 406–409 (2006)CrossRefGoogle Scholar
  21. 21.
    Kjeldsen, S.E., Naditch-Brule, L., Perlini, S., Zidek, W., Farsang, C.: Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the global cardiometabolic risk profile in patients with hypertension disease survey. J. Hypertens. 26(10), 2064–2070 (2008)PubMedCrossRefGoogle Scholar
  22. 22.
    Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults.: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 106, (25):3143-421 (2002)Google Scholar
  23. 23.
    Robert Koch Institute: Public use file BGS98, german national health interview and examination survey 1998. Robert Koch Institute, Berlin (2000)Google Scholar
  24. 24.
    Perez-Fernandez, R., Marino, A.F., Cadarso-Suarez, C., Botana, M.A., Tome, M.A., Solache, I., Rego-Iraeta, A., Mato, A.J.: Prevalence, awareness, treatment and control of hypertension in Galicia (Spain) and association with related diseases. J. Hum. Hypertens. 21(5), 366–373 (2007)PubMedGoogle Scholar
  25. 25.
    Mancia, G., Volpe, R., Boros, S., Ilardi, M., Giannattasio, C.: Cardiovascular risk profile and blood pressure control in Italian hypertensive patients under specialist care. J. Hypertens. 22(1), 51–57 (2004)PubMedCrossRefGoogle Scholar
  26. 26.
    Neuhauser, H., Ellert, U.: Estimation of the metabolic syndrome prevalence in the general population in Germany. J. Public Health 16, 221–227 (2008)CrossRefGoogle Scholar
  27. 27.
    Volpe, M., Tocci, G., Trimarco, B., Rosei, E.A., Borghi, C., Ambrosioni, E., Menotti, A., Zanchetti, A., Mancia, G.: Blood pressure control in Italy: results of recent surveys on hypertension. J. Hypertens. 25(7), 1491–1498 (2007)PubMedCrossRefGoogle Scholar
  28. 28.
    Wolf-Maier, K., Cooper, R.S., Banegas, J.R., Giampaoli, S., Hense, H.W., Joffres, M., Kastarinen, M., Poulter, N., Primatesta, P., Rodriguez-Artalejo, F., Stegmayr, B., Thamm, M., Tuomilehto, J., Vanuzzo, D., Vescio, F.: Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA 289(18), 2363–2369 (2003)PubMedCrossRefGoogle Scholar
  29. 29.
    Gabriel, R., Alonso, M., Segura, A., Tormo, M.J., Artigao, L.M., Banegas, J.R., Brotons, C., Elosua, R., Fernandez-Cruz, A., Muniz, J., Reviriego, B., Rigo, F.: Prevalence, geographic distribution and geographic variability of major cardiovascular risk factors in Spain. Pooled analysis of data from population-based epidemiological studies: the ERICE study. Rev. Esp. Cardiol. 61(10), 1030–1040 (2008)PubMedGoogle Scholar
  30. 30.
    Datamonitor: Stakeholder insight: metabolic syndrome. Datamonitor, New York (2004)Google Scholar
  31. 31.
    Frericks, H., Kievit, J., van Baalen, J.M., van Bockel, J.H.: Carotid recurrent stenosis and risk of ipsilateral stroke: a systematic review of the literature. Stroke 29(1), 244–250 (1998)PubMedGoogle Scholar
  32. 32.
    OECD: OECD health data 2007: statistics and indicators for 30 countries. OECD, Paris (2007)Google Scholar
  33. 33.
    Steckelings, U.M., Stoppelhaar, M., Sharma, A.M., Wittchen, H.U., Krause, P., Kupper, B., Kirch, W., Pittrow, D., Ritz, E., Goke, B., Lehnert, H., Tschope, D., Hofler, M., Pfister, H., Unger, T.: HYDRA: possible determinants of unsatisfactory hypertension control in german primary care patients. Blood Press. 13(2), 80–88 (2004)PubMedCrossRefGoogle Scholar
  34. 34.
    Dunbar-Jacob, J., Erlen, J.A., Schlenk, E.A., Ryan, C.M., Sereika, S.M., Doswell, W.M.: Adherence in chronic disease. Annu. Rev. Nurs. Res. 18, 48–90 (2000).PubMedGoogle Scholar
  35. 35.
    Corrao, G., Zambon, A., Parodi, A., Poluzzi, E., Baldi, I., Merlino, L., Cesana, G., Mancia, G.: Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J. Hypertens. 26(4), 819–824 (2008)PubMedCrossRefGoogle Scholar
  36. 36.
    Caro, J.J., Salas, M., Speckman, J.L., Raggio, G., Jackson, J.D.: Persistence with treatment for hypertension in actual practice. CMAJ 160(1), 31–37 (1999)PubMedGoogle Scholar
  37. 37.
    Esposti, L.D., Di Martino, M., Saragoni, S., Sgreccia, A., Capone, A., Buda, S., Esposti, E.D.: Pharmacoeconomics of antihypertensive drug treatment: an analysis of how long patients remain on various antihypertensive therapies. J. Clin. Hypertens. (Greenwich.) 6(2), 76–84 (2004)CrossRefGoogle Scholar
  38. 38.
    Mazzaglia, G., Mantovani, L.G., Sturkenboom, M.C., Filippi, A., Trifiro, G., Cricelli, C., Brignoli, O., Caputi, A.P.: Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J. Hypertens. 23(11), 2093–2100 (2005)PubMedCrossRefGoogle Scholar
  39. 39.
    Cordero, A., Laclaustra, M., Leon, M., Casasnovas, J.A., Grima, A., Luengo, E., Ordonez, B., Bergua, C., Bes, M., Pascual, I., Alegria, E.: Comparison of serum lipid values in subjects with and without the metabolic syndrome. Am. J. Cardiol. 102(4), 424–428 (2008)PubMedCrossRefGoogle Scholar
  40. 40.
    Gandjour, A., Stock, S.A.: National hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness. Health Policy 83(2–3), 257–267 (2007)PubMedCrossRefGoogle Scholar
  41. 41.
    Rovira, J., Badia, X., Pardell, H.: Cost of hypertension in Spain. J. Hum. Hypertens. 6(6), 481–483 (1992)PubMedGoogle Scholar
  42. 42.
    Hansson, L., Lloyd, A., Anderson, P., Kopp, Z.: Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press. 11(1), 35–45 (2002)PubMedCrossRefGoogle Scholar
  43. 43.
    Breekveldt-Postma, N.S., Penning-van Beest, F.J., Siiskonen, S.J., Falvey, H., Vincze, G., Klungel, O.H., Herings, R.M.: The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr. Med. Res. Opin. 24(1), 121–127 (2008)PubMedGoogle Scholar
  44. 44.
    Noto, D., Barbagallo, C.M., Cefalu, A.B., Falletta, A., Sapienza, M., Cavera, G., Amato, S., Pagano, M., Maggiore, M., Carroccio, A., Notarbartolo, A., Averna, M.R.: The metabolic syndrome predicts cardiovascular events in subjects with normal fasting glucose: results of a 15 years follow-up in a mediterranean population. Atherosclerosis 197(1), 147–153 (2008)PubMedCrossRefGoogle Scholar
  45. 45.
    Mar, J., Rodriguez-Artalejo, F.: Which is more important for the efficiency of hypertension treatment: hypertension stage, type of drug or therapeutic compliance? J. Hypertens. 19(1), 149–155 (2001)PubMedCrossRefGoogle Scholar
  46. 46.
    Taylor, M.J., Scuffham, P.A., McCollam, P.L., Newby, D.E.: Acute coronary syndromes in Europe: 1-year costs and outcomes. Curr. Med. Res. Opin. 23(3), 495–503 (2007)PubMedCrossRefGoogle Scholar
  47. 47.
    Mullins, C.D., Sikirica, M., Seneviratne, V., Ahn, J., Akhras, K.S.: Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 22(15), 1001–1014 (2004)PubMedCrossRefGoogle Scholar
  48. 48.
    Elliott, W.J., Meyer, P.M.: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201–207 (2007)PubMedCrossRefGoogle Scholar
  49. 49.
    Jonsson, B.: Revealing the cost of type ii diabetes in Europe. Diabetologia 45(7), S5–S12 (2002)PubMedCrossRefGoogle Scholar
  50. 50.
    Berghofer, A., Pischon, T., Reinhold, T., Apovian, C.M., Sharma, A.M., Willich, S.N.: Obesity prevalence from a european perspective: a systematic review. BMC Public Health 8, 200 (2008) schemas-com. Google Scholar
  51. 51.
    International Association for the Study of Obesity.: Adult overwieght and obesity in EU 27. http://www.iotf.org/database/documents/AdultEU27January2009pdf.pdf. (2009)
  52. 52.
    Curtis, L.H., Hammill, B.G., Bethel, M.A., Anstrom, K.J., Gottdiener, J.S., Schulman, K.A.: Costs of the metabolic syndrome in elderly individuals: findings from the cardiovascular health study. Diabetes Care 30(10), 2553–2558 (2007)PubMedCrossRefGoogle Scholar
  53. 53.
    Boudreau, D.M., Malone, D.C., Raebel, M.A., Fishman, P.A., Nichols, G.A., Feldstein, A.C., Boscoe, A.N., Ben Joseph, R.H., Magid, D.J., Okamoto, L.J.: Health care utilization and costs by metabolic syndrome risk factors. Metab. Syndr. Relat. Disord. 7(4), 305–314 (2009)PubMedCrossRefGoogle Scholar
  54. 54.
    Eckel, R.H., York, D.A., Rossner, S., Hubbard, V., Caterson, I., St Jeor, S.T., Hayman, L.L., Mullis, R.M., Blair, S.N.: Prevention conference vii: obesity, a worldwide epidemic related to heart disease and stroke: executive summary. Circulation 110(18), 2968–2975 (2004)PubMedCrossRefGoogle Scholar
  55. 55.
    Luders, S., Hammersen, F., Kulschewski, A., Venneklaas, U., Zuchner, C., Gansz, A., Schnieders, M., Pfarr, E., Sturm, C.D., Paar, W.D., Schrader, J.: Diagnosis of impaired glucose tolerance in hypertensive patients in daily clinical practice. Int. J. Clin. Pract. 59(6), 632–638 (2005)PubMedCrossRefGoogle Scholar
  56. 56.
    Lonati, C., Morganti, A., Comarella, L., Mancia, G., Zanchetti, A.: Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (Dia)bete study. J. Hypertens. 26(9), 1801–1808 (2008)PubMedCrossRefGoogle Scholar
  57. 57.
    Maetzel, A., Li, L.C., Pencharz, J., Tomlinson, G., Bombardier, C.: The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann. Rheum. Dis. 63(4), 395–401 (2004)PubMedCrossRefGoogle Scholar
  58. 58.
    Kiiskinen, U., Vartiainen, E., Puska, P., Aromaa, A.: Long-term cost and life-expectancy consequences of hypertension. J. Hypertens. 16(8), 1103–1112 (1998)PubMedCrossRefGoogle Scholar
  59. 59.
    Gami, A.S., Witt, B.J., Howard, D.E., Erwin, P.J., Gami, L.A., Somers, V.K., Montori, V.M.: Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 49(4), 403–414 (2007)PubMedCrossRefGoogle Scholar
  60. 60.
    Roux, L., Donaldson, C.: Economics and obesity: costing the problem or evaluating solutions? Obes. Res. 12(2), 173–179 (2004)PubMedCrossRefGoogle Scholar
  61. 61.
    National Institute for Health and Clinical Excellence.: CG34: hypertension: NICE clinical guidelines. National Institute for Health and Clinical Excellence, London (2006)Google Scholar
  62. 62.
    Mancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M.J., Cifkova, R., Clement, D., Coca, A., Dominiczak, A., Erdine, S., Fagard, R., Farsang, C., Grassi, G., Haller, H., Heagerty, A., Kjeldsen, S.E., Kiowski, W., Mallion, J.M., Manolis, A., Narkiewicz, K., Nilsson, P., Olsen, M.H., Rahn, K.H., Redon, J., Rodicio, J., Ruilope, L., Schmieder, R.E., Struijker-Boudier, H.A., Van Zwieten, P.A., Viigimaa, M., Zanchetti, A.: Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. Blood Press. 18(6), 308–347 (2009)PubMedCrossRefGoogle Scholar
  63. 63.
    Mathes, J., Kostev, K., Gabriel, A., Pirk, O., Schmieder, R.E.: Risks and costs of the first hypertension-associated event, compliance and persistence in niave hypertensive patients after initiating monotherapy. Value Health 11, A415 (2008)CrossRefGoogle Scholar
  64. 64.
    Kurtz, T.W.: New treatment strategies for patients with hypertension and insulin resistance. Am. J. Med. 119(Suppl 1), S24–S30 (2006)PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Eberhard Wille
    • 1
    Email author
  • Jürgen Scholze
    • 2
  • Eduardo Alegria
    • 3
  • Claudio Ferri
    • 4
  • Sue Langham
    • 5
  • Warren Stevens
    • 6
  • David Jeffries
    • 7
  • Kerstin Uhl-Hochgraeber
    • 8
  1. 1.Fakultät für VolkswirtschaftslehreMannheimGermany
  2. 2.Department of Medicine, Outpatient Clinic, CCMCharite-Universitatsmedizin BerlinBerlinGermany
  3. 3.Servicio de CardiologíaPoliclínica GipuzkoaSan SebastiánSpain
  4. 4.Division of Internal Medicine, Hypertension and Cardiovascular Prevention Center, Department of Internal Medicine and Public Health, San Salvatore HospitalUniversity of L’AquilaL’AquilaItaly
  5. 5.Independent Health EconomistManchesterUK
  6. 6.Independent Health EconomistBostonUSA
  7. 7.Statistics and Data ManagementMRC Tropical Disease Research UnitBanjulGambia
  8. 8.Global Health Economics and Outcomes ResearchBayer Schering Pharma AGBerlinGermany

Personalised recommendations